I suspect the underwriters selling out their position to prepare for the next wave. The announcement of pivot trial and IDE progress should not be too far off offer after the completion of 12 months clinical data just announced yesterday.
Not advice, DYOR
AVR Price at posting:
$9.80 Sentiment: None Disclosure: Held
A personalised tool to help users track selected stocks. Delivering real-time notifications on price updates, announcements, and performance stats on each to help make informed investment decisions.
(20min delay)